Sarepta Continued Climbing
Shares of Sarepta Therapeutics Inc. (Nasdaq: SRPT) continued climbing by gaining $1.42 to close at $15.82 after a news report yesterday highlighted positive results in a small, mid-stage trial of the company's Duchenne Muscular Dystrophy treatment Eteplirsen.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here